600613.SHG Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
- Market cap
- CNY 3.51B
- P/E
- 328.5x
- P/B
- 1.46x
- ROE
- 1.2%
- Dividend yield
- 2.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600613.SHG undervalued?
Graham numberThe Graham number of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A fundamental analysis
No fundamental analysis for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A yet.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sales of pharmaceuticals in China and internationally. The company offers patented anti-tumor drugs; topical antibacterial series; products for hypertension, hyperlipidemia, and hyperglycemia chronic diseases; classic Chinese medicine cough relief series; classic tonic product series; Miao medicine for strengthening muscles and…
Full company profileShanghai Shenqi Pharmaceutical Investment Management Co Ltd A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.60B | 1.74B | 1.85B | 1.93B | 1.82B | 2.30B | 2.39B | 2.34B | 2.05B | 1.95B | 1.67B |
| Gross Profit | 1.06B | 1.04B | 1.13B | 1.21B | 1.07B | 1.38B | 1.26B | 1.15B | 952M | 881M | 739M |
| Operating Income | 195M | 139M | 129M | 108M | -338M | 101M | 65.9M | 82.8M | 91.7M | 111M | 94.6M |
| EBITDA | 263M | 205M | 183M | 174M | -281M | 166M | 167M | 181M | 180M | 168M | 64.0M |
| Net Income | 182M | 130M | 106M | 84.0M | -341M | 69.6M | 48.5M | 57.0M | 71.4M | 38.2M | 27.6M |
| EPS | 0.34 | 0.24 | 0.20 | 0.16 | -0.64 | 0.13 | 0.09 | 0.11 | 0.13 | 0.07 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 3.00B | 3.10B | 3.13B | 3.56B | 3.10B | 3.15B | 3.38B | 3.28B | 3.12B | 3.15B | 2.92B |
| Total Liabilities | 568M | 565M | 528M | 895M | 770M | 756M | 1.01B | 889M | 689M | 748M | 542M |
| Shareholders' Equity | 2.36B | 2.46B | 2.54B | 2.62B | 2.28B | 2.34B | 2.33B | 2.34B | 2.36B | 2.32B | 2.29B |
| Cash & Short-term Investments | 309M | 284M | 206M | 596M | 481M | 494M | 656M | 736M | 800M | 594M | 558M |
| Total Debt | 80.0M | 128M | 27.1M | 403M | 344M | 312M | 286M | 253M | 167M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 570K | 67.0M | 149M | 128M | 99.1M | 184M | 319M | 216M | 208M | 124M | - |
| Capital Expenditure | 42.9M | 109M | 110M | 77.0M | 96.3M | 86.0M | 26.6M | 24.5M | 36.4M | 33.2M | 12.8M |
| Free Cash Flow | -42.3M | -41.9M | 38.3M | 51.3M | 2.79M | 98.3M | 293M | 191M | 171M | 91.3M | 177M |
| Ratios | |||||||||||
| ROE | 7.7% | 5.3% | 4.2% | 3.2% | -15.0% | 3.0% | 2.1% | 2.4% | 3.0% | 1.6% | 1.2% |
| ROA | 6.1% | 4.2% | 3.4% | 2.4% | -11.0% | 2.2% | 1.4% | 1.7% | 2.3% | 1.2% | 0.9% |
| Net Profit Margin | 11.4% | 7.5% | 5.7% | 4.4% | -18.8% | 3.0% | 2.0% | 2.4% | 3.5% | 2.0% | 1.7% |
| Debt to Equity | 0.03x | 0.05x | 0.01x | 0.15x | 0.15x | 0.13x | 0.12x | 0.11x | 0.07x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A dividends
- Dividend yield
- 2.51%
- Forward dividend
- 0.07 CNY
- Payout ratio
- 230.7%
- Ex-dividend date
- Jun 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 88.2M | 0.17 | 230.7% |
| 2024 | CNY 64.2M | 0.12 | 89.9% |
| 2023 | CNY 66.3M | 0.13 | 116.3% |
| 2022 | CNY 53.5M | 0.10 | 110.1% |
| 2021 | CNY 3.97M | 0.01 | 5.7% |
| 2020 | CNY 5.83M | 0.01 | - |
| 2019 | CNY 4.41M | 0.01 | 5.3% |
| 2018 | CNY 22.0M | 0.04 | 20.8% |
| 2017 | CNY 29.6M | 0.05 | 22.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12:10 on Jul 6, 2015.
Who owns Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
- Insiders 43.81%
- Institutions 0.61%
- Public & others 55.57%
- Shares outstanding 479M
- Free float 312M
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A company profile
- Company name
- Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
- Ticker
- 600613.SHG
- ISIN
- CNE000000453
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 20, 1992
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,196
- Fiscal year end
- December
- Address
- Changfa Building, Shanghai, China, 200003
- Phone
- 86 21 5375 0009
- Website
- gzsq.com
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sales of pharmaceuticals in China and internationally. The company offers patented anti-tumor drugs; topical antibacterial series; products for hypertension, hyperlipidemia, and hyperglycemia chronic diseases; classic Chinese medicine cough relief series; classic tonic product series; Miao medicine for strengthening muscles and bones series; and magical doll medicine series. It also provides toothache relief drops; parsnicillin tablets, compound amino acid vitamin capsules, compound chlorhexidine dexamethasone, nasal and mouth cleansing spray, constipation relief capsules, anwei tablets, motherwort paste, gynecological menstrual regulating tablets, Sangju cold tablets, hawthorn granules, isatis root granules, col and cough syrup, and gastritis relief granules, as well as acetaminophen, caffeine, and flavoxate tablets. The companys products are used for therapeutic areas such as anti-tumor, cold and cough relief, cardiovascular and cerebrovascular diseases, rheumatic bone pain, antifungal, tonifying and calming mind, and gynecological diseases. In addition, it is involved in wholesale and retail trade, and culture and art businesses; provision of software and information technology services. It also exports its products. The company was founded in 1992 and is based in Shanghai, China.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A management
4- Mr. Feng BinGM & Director · born 1972
- Mr. Zhimian ChenCFO & Director · born 1971
- Mr. Kejing WuBoard Secretary · born 1977
- Mr. Xiajuan WangAccounting Supervisor